Drug
Gocatamig
Gocatamig: highest development phase Phase 3, developed by Merck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Gocatamig NCT07908537 | Phase 3 | Small Cell Lung Cancer |
| Gocatamig NCT07227597 | Phase 1/2 | Small Cell Lung Cancer Extensive Stage |
| Gocatamig NCT06780137 | Phase 1/2 | Small Cell Lung Cancer |
Latest
No recent events.
Follow Gocatamig on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.